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The purpose of this study was to explore risk factors affecting
the incidence of chronic kidney disease (CKD) in general
population. We conducted a 10-year follow-up study with
123 764 (male: 41 012, female: 82 752) adults aged 40 years
and over who received community-based annual
examinations. The primary outcome for the analysis was the
development of CKD during the follow-up period. Predictors
for the development of CKD were obtained by the significant
hazard ratios (HR) in Cox regression model by sex. During the
follow-up period, 4307 subjects (male: 2048, female: 2259)
developed CKD stage I or II, and 19 411 subjects (male: 4257,
female: 15 154) developed CKD stage III or higher. The
baseline-adjusted predictor of developing CKD included age,
glomerular filtration rate, hematuria, hypertension, diabetes,
serum lipids, obesity, smoking status, and consumption of
alcohol. Treated diabetes in male subjects, and treated
hypertension, systolic blood pressure 4160 mm Hg and/or
diastolic blood pressure 4100 mm Hg, diabetes, and treated
diabetes in female subjects were associated with more than a
doubling of the HR. For the development of CKD stage III or
higher, proteinuria ofXþ þ , and proteinuria and hematuria
were associated with more than a doubling of the HR in male
subjects. The prevalence of newly developed CKD over 10
years was 23 718 subjects (19.2%) in adults. This study
suggested that not only hypertension and diabetes but also
several metabolic abnormalities were independent risk
factors for developing CKD.
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The number of the patients with end-stage renal diseases
(ESRD) has increased by about 9% per year in the USA,
about 4% per year in most of European countries,1 and about
7% per year in Japan.2 The increased incidence of ESRD is
recognized as a major public health problem worldwide. To
prevent an increase in the number of ESRD patients in Japan,
a dipstick urine examination has been available annually for
every school child since 1973, for every working adult since
1972, and for every resident older than 40 years of age since
1982 under the auspices of local governments and the
Ministry of Health, Labor and Welfare of Japan. Also, an
annual measurement of serum creatinine was started in 1992
for every resident older than 40 years of age.3,4 However,
there have been few reports concerning the effects and
outcomes of this screening program. In 2002, the Kidney
Disease Outcomes Quality Initiative (K/DOQI) of the
National Kidney Foundation (NKF) gave a definition and
classification system for chronic kidney disease (CKD).5 The
definition and classification of CKD were accepted by the
international board of directors of Kidney Disease: Improv-
ing Global Outcomes (KDIGO).6 CKD was defined in five
stages, based on the appearance of proteinuria and glome-
rular filtration rate (GFR) levels. To estimate GFR, the
modification of diet in renal disease (MDRD) formula was
recommended for its accuracy in elderly subjects.7 It was
estimated that of the 19.2 million US adults with CKD,
patients with early-stage CKD had no symptoms and the
majority of individuals in early stage of CKD had gone
undiagnosed even in developed countries.8 Furthermore,
patients with CKD have an increased risk of not only ESRD,
but also poor cardiovascular outcomes and death.9–11 A vast
number of those with moderate CKD die before they develop
more advanced CKD.12
In this study, we used mass screening data from a
community-based annual health-check held in Ibaraki
prefecture, Japan. We measured the prevalence of CKD and
its yearly changes in subjects who were continuously
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monitored over 10 years. From this study, we found the
yearly incidence of CKD in a large community-based popu-
lation older than 40 years, and tried to find risk factors for
the development of CKD among the subjects during the
10-year follow-up period. Based on our results, strategies for
effective methods to prevent the development of CKD among
the general population could be devised.
RESULTS
Followed-up subjects
The age distribution of the subjects is shown in Figure 1.
Table 1 shows baseline characteristics of the follow-up
subjects. Male subjects were older, more frequently had
diabetes, were hypertensive, and had smoking and drinking
habits, whereas female subjects often had hematuria. A lower
number of male subjects was observed in this study because
most male residents under 60 years did not receive their
annual physical checks at community centers, but at their
work places.
Incidence of CKD stage I or II
During the follow-up period, 4307 subjects (male: 2048,
female: 2259) developed CKD stage I or II. The incidence of
developing proteinuria also increased with age (Figure 2).
Male subjects developed CKD I or II more frequently than
female subjects. The predictors of developing proteinuria
included age, hematuria, hypertension, impaired glucose
tolerance (IGT), diabetes, serum lipids, obesity, smoking
status, and consumption of alcohol (inverse relationship)
(Table 2). Baseline-adjusted predictors of developing proteinuria
included treated hypertension (hazard ratio (HR), 2.28; 95%
confidence interval (CI), 2.07–2.52) in female subjects,
systolic blood pressure 4160 mm Hg and/or diastolic blood
pressure 4100 mm Hg (HR, 2.17; 95% CI, 1.85–2.54) in
female subjects, and treated diabetes (HR, 2.48; 95% CI,
2.12–2.91 in male subjects; HR, 2.91; 95% CI, 2.46–3.45 in
female subjects), which were associated with more than a
doubling of the HR of developing proteinuria. The HR of
developing proteinuria increased with elevations in blood
pressure levels in both genders. In the subjects with
hypercholesterolemia, low high-density lipoprotein choles-
terol (HDL-C), and hypertriglyceridemia, the HR of deve-
loping proteinuria increased in both genders. Obesity
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Figure 1 | Age distribution of the subjects. A lower number of male
subjects under 60 years was observed in this study.
Table 1 | Baseline characteristics of the followed up subjects by sex
Male (n=41 012) Female (n=82 752)
Values s.d. or % Values s.d. or %
Mean age, s.d. 61.8 10.2 58.3 10.0
Creatinine (mg/dl), s.d. 1.0 0.1 0.8 0.1
Estimated GFR (ml/min/1.73 m2), s.d. 81.9 14.5 79.8 14.2
Proteninuria, n, % 638 1.6 521 0.6
Proteninuria and hematuria, n, % 248 0.6 399 0.5
Hematuria alone, n, % 3424 8.3 15 443 18.7
Hypertension, n, % 20 569 50.2 31 695 38.3
Treated hypertension, n, % among hypertensive subjects 8613 41.9 15 609 49.2
Impaired glucose tolerance n, % 6046 14.7 6998 8.5
Diabetes, n, % 3007 7.3 3329 4.0
Diabetes, with medication, n, % among diabetic subjects 1468 48.8 1769 53.1
Total cholesterol (mg/dl), s.d. 193 33.5 210 34.7
HDL-C (mg/dl), s.d. 52.5 14.7 56.8 14.1
Triglyceride (mg/dl), s.d. 147.3 94.4 136.5 78.6
Body mass index (kg/m2), s.d. 23.2 2.9 23.5 3.2
Smoking
Current, n, % 19 372 47.2 3437 4.2
Previous, n % 12 104 29.5 441 0.5
Alcohol consumption
Occasional n, % 5223 12.7 4813 5.8
Ethanol o20 g/day, n, % 19 168 46.7 2944 3.6
Ethanol 420 g/day, n,% 2552 6.2 80 0.1
GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol.
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increased the HR of developing proteinuria by 42% in male
subjects and 56% in female subjects, and current smoking
increased the HR by 26% in male subjects and 40% in
female subjects. Alcohol consumption of less than 20 g/day
decreased the HR of developing proteinuria, but this effect
was diminished by consumption of alcohol of more than
20 g/day.
Figure 3 shows the trend of annual incidence of CKD I or
II among the follow-up subjects. In the early years of follow-
up, a higher incidence of developing proteinuria was
observed. Subjects with trace proteinuria often developed
apparent CKD I or II in the early years. However, after 1998,
the trend of annual incidence of CKD I or II was about 0.4%
per year in male subjects and about 0.2% per year in female
subjects.
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Figure 2 | Age-specific incidence rate of CKD stage I or II by sex.
During the follow-up period, 4307 (male: 2048, female: 2259)
developed CKD stage I or II. The incidence of developing proteinuria
also increased with age. Male subjects more frequently developed
CKD I or II than female subjects.
Table 2 | The predictors for developing CKD stage I or II during 10-year follow-up period
Male Female
Predictors HR 95% CI P HR 95% CI P
Age 1.02 1.02–1.03 o0.0001* 1.03 1.03–1.04 o0.0001*
GFR 0.99 0.99–1.00 0.0005* 1.00 1.00–1.01 0.1401
Hematuria () 1.00 1.00
Hematuria (+) 1.24 1.04–1.47 0.0142* 1.30 1.16–1.46 o0.0001*
Hematuria 4++ 1.66 1.39–1.99 o0.0001* 1.60 1.43–1.79 o0.0001*
BP 140/90 mm Hg 1.00 1.00
BP 140–150/90–95 mm Hg 1.21 1.08–1.35 0.0008* 1.51 1.34–1.69 o0.0001*
BP 150–160/95–100 mm Hg 1.44 1.24–1.67 o0.0001* 1.67 1.45–1.93 o0.0001*
BP 160+/100+ mm Hg 1.73 1.48–2.02 o0.0001* 2.17 1.85–2.54 o0.0001*
Treated hypertension 1.85 1.66–2.07 o0.0001* 2.28 2.07–2.52 o0.0001*
IGT () 1.00 1.00
IGT (+) 1.21 1.08–1.35 0.0011* 1.19 1.05–1.35 0.0055*
Diabetes () 1.00 1.00
Diabetes (+) 1.76 1.47–2.11 o0.0001* 2.14 1.75–2.63 o0.0001*
Treated diabetes 2.48 2.12–2.91 o0.0001* 2.91 2.46–3.45 o0.0001*
Hypercholesterolemia () 1.00 1.00
Hypercholesterolemia (+) 1.13 1.02–1.25 0.0225* 1.13 1.04–1.22 0.0025*
Low HDL-C () 1.00 1.00
Low HDL-C (+) 1.14 1.02–1.27 0.0184* 1.17 1.03–1.32 0.0122*
Hypertriglyceridemia () 1.00 1.00
Hypertriglyceridemia (+) 1.12 1.02–1.23 0.0134* 1.20 1.10–1.31 o0.0001*
Obesity () 1.00 1.00
Obesity (+) 1.42 1.29–1.55 o0.0001* 1.56 1.44–1.69 o0.0001*
Never smoking 1.00 1.00
Previous smoking 1.05 0.93–1.17 0.4486 1.54 0.98–2.42 0.0617
Current smoking 1.26 1.14–1.41 o0.0001* 1.40 1.16–1.69 0.0005*
Never drinker 1.00 1.00
Occasional drinker 1.03 0.90–1.17 0.6577 0.96 0.80–1.14 0.637
Ethanol o20 g/day 0.86 0.78–0.95 0.002* 0.80 0.63–1.02 0.0685
Ethanol 420 g/day 1.04 0.86–1.25 0.5057 1.05 0.26–4.24 0.9444
BP, blood pressure; CI, confidence interval; CKD, chronic kidney disease; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; IGT, impaired glucose tolerance.
*Po0.05.
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Figure 3 | Trend of annual incidence rate of CKD stage I or stage II
by sex. In the early years of follow-up, a higher incidence of
developing proteinuria was observed. Subjects with trace proteinuria
often developed apparent CKD I or II in the early years. However,
after 1998, the yearly incidence of CKD I or II was about 0.4% for male
subjects and about 0.2% for female subjects.
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Incidence of CKD stage III or higher
During the follow-up period, 19 411 subjects (male: 4257,
female: 15 154) exhibited GFRo60 ml/min/1.73 m2. The
incidence of CKD stage III or higher increased with age
(Figure 4). The predictors of developing CKD stage III or
higher were age, proteinuria, hematuria, hypertension, trea-
ted diabetes, and smoking status. Baseline-adjusted predic-
tors of developing CKD stage III or higher included
proteinuria (Xþ þ ) (HR, 2.26; 95% CI, 1.71–2.99), conco-
mitant proteinuria, and hematuria (HR, 2.32; 95% CI,
1.81–2.97) in male subjects, which were associated with more
than a doubling of the HR. Treated hypertension increased
the HR of developing renal failure by 39%, and treated
diabetes increased the HR by 20%; however, alcohol
consumption of less than 20 g/day decreased the HR of
developing CKD stage III or higher by 8% in male subjects
and 9% in female subjects. Treated hypertension increased
the HR of developing CKD stage III or higher by 39% (20%
in female), and taking diabetes medication increased the HR
by 20% in male subjects and 12% in female subjects. A
reduced risk for developing CKD stage III in IGT or diabetes
was observed (Table 3).
Figure 5 shows the yearly incidence of CKD stage III or
higher among the follow-up subjects. In the early years of
follow-up, a higher incidence of developing CKD stage III or
higher was also observed. However, after 1998, the yearly
incidence of CKD stage III or higher was about 0.8% per year
in male subjects and about 1.5% per year in female subjects.
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Figure 4 | Age-specific incidence rate of CKD stage III or higher by
sex. During the follow-up period, 19 411 (male: 4257, female: 15 154)
exhibited GFRo60 ml/min/1.73 m2. The incidence of CKD stage III or
higher increased with age.
Table 3 | The predictors for developing CKD stage III or higher during 10-year follow-up period
Male Female
Predictors HR 95% CI P HR 95% CI P
Age 1.03 1.03–1.04 o0.0001* 1.05 1.05–1.06 o0.0001*
GFR 0.87 0.87–0.88 o0.0001* 0.90 0.89–0.90 o0.0001*
Proteinuria () 1.00 1.00
Proteinuria (+) 1.66 1.34–2.07 o0.0001* 1.36 1.10–1.69 0.0046*
Proteinuria 4++ 2.26 1.71–2.99 o0.0001* 1.78 1.37–2.30 o0.0001*
Proteinuria and hematuria 2.32 1.81–2.97 o0.0001* 1.43 1.18–1.73 0.0003*
Hematuria () 1.00 1.00
Hematuria (+) 1.23 1.10–1.39 0.0004* 1.07 1.02–1.13 0.0043*
Hematuria 4++ 1.31 1.15–1.50 o0.0001* 1.07 1.01–1.12 0.0128*
BP 140/90 mm Hg 1.00 1.00
BP 140–150/90–95 mm Hg 1.13 1.04–1.23 0.0035* 1.08 1.04–1.14 0.0007*
BP 150–160/95–100 mm Hg 1.17 1.05–1.29 0.0034* 1.19 1.12–1.26 o0.0001*
BP 160+/100+ mm Hg 1.33 1.19–1.48 o0.0001* 1.26 1.17–1.35 o0.0001*
Treated hypertention 1.39 1.30–1.50 o0.0001* 1.20 1.16–1.25 o0.0001*
IGT () 1.00 1.00
IGT (+) 0.86 0.79–0.93 0.0002* 0.80 0.76–0.85 o0.0001*
Diabetes () 1.00 1.00
Diabetes (+) 0.71 0.61–0.84 o0.0001* 0.76 0.68–0.86 o0.0001*
Treated diabetes 1.20 1.05–1.38 o0.0001* 1.12 1.01–1.24 o0.0001*
Hypercholesterolemia () 1.00 1.00
Hypercholesterolemia (+) 1.01 0.94–1.08 0.8865 0.95 0.92–0.98 0.0026*
Low HDL-C () 1.00 1.00
Low HDL-C (+) 1.10 1.03–1.19 0.0084* 1.02 0.97–1.08 0.4101
Hypertriglyceridemia () 1.00 1.00
Hypertriglyceridemia (+) 1.04 0.98–1.11 0.2121 1.10 1.07–1.14 o0.0001*
Obesity () 1.00 1.00
Obesity (+) 1.03 0.96–1.10 0.3979 1.06 1.03–1.10 0.0006*
Never smoking 1.00 1.00
Previous smoking 1.05 0.97–1.13 0.2232 1.10 0.88–1.37 0.4007
Current smoking 1.13 1.05–1.22 0.0007* 1.16 1.06–1.26 0.0009*
Never drinker 1.00 1.00
Occasional drinker 0.96 0.88–1.05 0.3721 0.89 0.83–0.97 0.0052*
Ethanol o20 g/day 0.92 0.86–0.98 0.0065* 0.91 0.83–1.00 0.0414*
Ethanol 420 g/day 0.93 0.79–1.10 0.4214 0.59 0.22–1.56 0.2846
BP, blood pressure; CI, confidence interval; CKD, chronic kidney disease; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; IGT, impaired glucose tolerance.
*Po0.05.
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Prevalence of CKD among the cohorts
During the 10-year follow-up period, we found that 327
subjects had CKD stage I, 1721 subjects had CKD stage II,
and 4455 subjects had CKD stage III or higher, of whom 198
subjects already had proteinuria at the baseline (Table 4).
Consequently, 4257 male subjects newly developed CKD
stage III or higher. We found that 295 female subjects had
CKD stage I, 1964 had CKD stage II, and 15 401 had CKD
stage III or higher, of whom 247 already had proteinuria at
the baseline. Consequently, 15 154 female subjects newly
developed CKD stage III or higher. Overall, the prevalence of
newly developed CKD over the 10 years was 23 718 subjects
(19.2%) over 40 years of age.
DISCUSSION
The subjects in the present study were a large group of
community-based individuals who underwent annual health
examinations under the auspices of the local governments
and the Ministry of Health, Labor and Welfare of Japan. Our
study demonstrated that 23 718 subjects (19.2%) had deve-
loped CKD during the 10-year follow-up period. Predicting
factors for the development of CKD showed a slight
difference between CKD stage I and II (proteinuria), and
CKD stage III or higher, as well as between genders. Age,
blood pressure levels, and smoking habits had the same effect
on all of CKD stages. However, diabetes, obesity, hyperlipid-
emia, and alcohol consumption had different effects on the
incidence of each CKD stage.
The prevalence of proteinuria and renal failure were
influenced by age and gender.13,14 Age is recognized as an
independent risk factor for renal disease15 and our findings of
increased incidence of proteinuria with aging are consistent
with previous reports.13,16–18 Also, an increased incidence of
renal dysfunction with aging is consistent with previous
reports. In subjects older than 50 years, the percentage of
sclerotic glomeruli increased, with a range of 0.5–36%,19 due
to glomerular ischemia secondary to the changes in renal
blood flow that occur with aging.20,21 These changes resulted
in not only progressive renal dysfunction but also proteinuria
due to glomerular hypertension and hyperfiltration of
residual glomeruli.
Proteinuria and hypertension are recognized as strong
predictors for progression of renal dysfunction.22 Klag et al.
reported a strong, graded relationship between blood
pressure and ESRD in men.23 We found a graded relationship
between blood pressure and newly onset CKD in both
genders. Furthermore, the subjects with treated hypertension
had a higher risk for developing CKD than other hyper-
tensive subjects: these subjects may have had a long-standing
history of hypertension resulting in vascular damage. Recent
studies have suggested that strict blood pressure control and
certain classes of antihypertensive medications, such as
angiotensin-converting enzyme inhibitors or angiotensin
receptor antagonists, reduce proteinuria and prevent pro-
gression to ESRD.22 In this study, we had no information
about any antihypertensive drugs which the treated hyper-
tensive subjects might have been taking. Further prospective
studies are needed to clarify the effectiveness of strict blood
pressure control, or certain classes of antihypertensive medi-
cation such as angiotensin-converting enzyme inhibitors
or angiotensin receptor antagonists, on the development
of CKD.
Diabetes is also considered to be a predictor for develop-
ing proteinuria13,18 and progression to renal dysfunction.24,25
Our findings of an increased incidence of proteinuria with
diabetes are consistent with previous reports. However, a
reduced risk for developing CKD stage III in IGT or diabetes
was observed. In general, patients with diabetes exhibited
small amount of albumin in their urine in 20–40% of patients
with type I or type II diabetes after 10–15 years of stable renal
function or even hyperfiltration.26 Consequently, some
subjects with IGT or diabetes showed hyperfiltration, and
these subjects maintained their renal function within the
normal range, whereas patients treated for diabetes, who had
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Figure 5 | Trend of annual incidence rate of CKD stage III or
higher by sex. In the early years of follow-up, a higher incidence of
developing CKD stage III or higher was also observed. However, after
1998, the yearly incidence of CKD stage III or higher was about 0.8%
for male subjects and about 1.5% for female subjects.
Table 4 | Prevalence of newly developed CKD among the
subjects
Age (years)
40–49 50–59 60–69 70– Total %
Male
Stage I 64 94 147 22 327 0.82
Stage II 147 276 867 431 1721 4.30
Stage III– 105 540 2343 1467 4257 10.38
Female
Stage I 93 141 52 9 295 0.36
Stage II 213 490 876 385 1964 2.41
Stage III– 742 3531 8063 3065 15 154 18.31
CKD, chronic kidney disease.
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long-standing diabetic status, often progressed to CKD stage
III or higher during the follow-up period.
Hyperlipidemia is also considered to be a risk factor
for developing CKD.25,27 Although hypertriglyceridemia is
regarded as an independent risk factor for developing
proteinuria,28,29 the effect of total cholesterol and HDL-C
on proteinuria development is controversial.18 Metcalf et al.
reported that the degree of albuminuria showed piecewise
log-linear relationships with hypertriglyceridemia and hyper-
cholesterolemia, and a negative piecewise linear relationship
with HDL-C.17 On the contrary, Tozawa et al. reported that
hypertriglyceridemia was a significant predictor of protein-
uria, but hypercholesterolemia and low HDL-C were not
within three years follow-up period.28 The effect of hyper-
lipidemia on progression of renal dysfunction produced
more complex results. Schaeffner et al. reported that the
relative risk for elevated creatinine was 1.77 for hypercholes-
terolemia, and 2.16 for low HDL-C in male subjects.27
However, Munter et al. reported that the relative risk for
elevated creatinine was 1.65 for hypertriglyceridemia and
2.13 for low HDL-C, but that hypercholesterolemia was not
a significant risk factor.25 Several other community-based
studies showed that total cholesterol was not a significant risk
factor for developing renal dysfunction.30 From our results,
long-term hypercholesterolemia, hypertriglyceridemia, and
low HDL-C were risk factors for developing proteinuria
in both genders, whereas low HDL-C in male subjects and
hypertriglyceridemia in female subjects were independent
relative risk factors for developing renal dysfunction. Further-
more, female subjects with hypercholesterolemia showed a
reduced risk of developing renal dysfunction. Although
cholesterol-lowering treatment showed favorable effects on
renal function,31,32 there are no large studies proving the
effect of lipid reduction on the progression of renal disease.
Our study confirmed that hyperlipidemia and low HDL-C
were independent risk factors for proteinuria, and as
mentioned above, proteinuria is regarded as a strong pre-
dictor for renal dysfunction. However, these lipidemic
changes did not persistently affect renal function during the
10-year follow-up. Further long-term studies are needed to
clarify this point.
Obesity is a known risk factor for proteinuria.13 The renal
effects of obesity include an increased glomerular filtration
rate, increased renal blood flow, and renal hypertrophy,33 and
weight loss of obese subjects ameliorates these abnormalities,
as well as reducing urinary protein excretion.33 Our findings
are consistent with other reports that obese subjects showed
a 42% increased risk of developing proteinuria for male
subjects, and a 56% increase for female subjects. However,
the effect of obesity on developing CKD III or a later stage
remains controversial. Iseki et al.34 reported that obesity
was not a major risk factor for development of ESRD in a
10-year follow-up period. Recently, Fox et al.30 and Iseki
et al.35 reported that obesity was an independent risk factor
for development for renal dysfunction following 17–18.5
years follow-up. Our cohorts showed a 6% increased risk of
developing renal dysfunction only in female subjects over
a 10-year follow-up period. Consequently, it is possible
that obesity might be a significant relative risk for renal
dysfunction after a longer follow-up duration in both
genders.
Smoking is an independent risk factor for the develop-
ment of CKD.36 Our cohort also showed that smoking
induced increased the risk of proteinuria and renal dysfunc-
tion in both genders. However, being an ex-smoker was not a
risk factor for developing proteinuria and renal dysfunction.
Consequently, cessation of smoking has a favorable effect
on preventing the development of CKD.
Several population-based studies have suggested that
moderate alcohol intake has a protective effect on cardio-
vascular death.37,38 The effects of alcohol consumption on
development of CKD remain controversial. Knight et al.
reported that moderate alcohol intake had no substantial
adverse effect on renal function in women,39 whereas
Perneger et al. reported significantly increased odds of
developing ESRD in subjects who drank more than two
alcoholic beverages per day.40 As for developing CKD, our
cohorts showed that alcohol intake of less than 20 g/day
reduced the risk of developing proteinuria in men and
reduced the risk of developing renal dysfunction in both
genders. This favorable effect was diminished after ethanol
intake of more than 20 g/day. We did not study the type of
alcoholic beverage among our cohorts, although there is a
possibility that the type of alcohol may influence the effects.38
However, it is valuable to know that regular moderate alcohol
consumption protects against developing CKD, but this effect
is diminished after consuming more than 20 g/day of ethanol
among general population.
The prevalence of CKD among our study population at
the baseline in 1993 was 8.5% for male and 9.1% for female
subjects. Subsequently, 19.2% of the cohort developed CKD
over the next 10 years. A previous report suggested that the
prevalence of CKD was 16% of a study population among
individuals aged 45 years and older.41 There may have been
selection bias in our study population, because our subjects
received annual physical checks for 10 years, and subjects
with severe disorders, or signs or symptoms tend to attend
clinics and hospitals, and thus these subjects did not receive
annual physical checks. Consequently, the prevalence of CKD
might have increased if we had observed these subjects.
From our study, several lifestyle-related and co-morbid
conditions affected the development of CKD. The effect of
active health-care education and intervention in our cohort
to prevent CKD development should be studied in the near
future.
In summary, the prevalence of newly developed CKD over
10 years was 23 718 (19.2%) in adults over 40 years of age.
The subjects of the present study were a large group of
community-based individuals who underwent annual health
examinations under the auspices of the local governments
and the Ministry of Health, Labor and Welfare of Japan. We
found several significant risk factors for developing CKD.
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Blood pressure levels, diabetes status, serum lipid status,
obesity, smoking, and alcohol consumption affected the
development of CKD. Further studies are needed to clarify
the effects of controlling these risk factors on the prevention
of CKD.
MATERIALS AND METHODS
Subjects
All the subjects in this study were participants in the annual health
examination held in Ibaraki prefecture, Japan, between 1993 and
2003. At the initial screening, a total of 191 006 adults (male: 65 368,
female: 125 698) aged 40 years or over underwent an annual health
examination at the Ibaraki health-care center in 1993. The study
protocol was approved by the Ethics Committee of Ibaraki
Prefectural Office. CKD and its stages were defined from estimated
GFR of o60 ml/min/1.73 m2 or dipstick proteinuria (X1þ ) as
follows: Stage 1 CKD was defined as an estimated (e)GFR X90 ml/
min/1.73 m2 and proteinuria. Stage 2 CKD was eGFR 60–89 ml/min/
1.73 m2 and proteinuria. Stages 3–5 CKD were classified to the level
of kidney function (eGFR 30–59, 15–29, and o15 ml/min/1.73 m2,
respectively), regardless of the presence of other markers of kidney
damage.5
The number of patients with CKD and the classifications of all
participants at the initial screening in 1993 are shown in Table 5. In
total, 5521 male subjects of 65 368 subjects (8.4%) had CKD and
11 454 female subjects of 125 698 (9.1%) had CKD. For the follow-up
study, we excluded subjects who already had CKD stage III and over,
and 67 302 (male: 24 356, female: 42 936) who did not receive annual
examinations continuously. For the follow-up study on developing
proteinuria, 1806 (male: 886, female: 920) were excluded because
they had proteinuria (CKD I or II) at the initial screening in 1993.
All subjects were interviewed to obtain information regarding
alcohol intake, smoking habits, and medical history, including use of
antihypertensive and diabetes medications. Blood pressure was
measured after several minutes’ rest in a sitting position with a
mercury sphygmomanometer or automatic device. The blood
pressure measurement was repeated if the first reading was outside
the normal range.
Proteinuria and hematuria were tested using dipsticks (Ames
Hemacombisticks; Bayer-Sankyo Ltd, Tokyo, Japan). A test result of
‘1þ ’ or more was defined as positive. Serum creatinine concentra-
tion was measured by a modified Jaffe method (creatinine HR,
Wako Pure Chemicals Industries, Ltd, Osaka, Japan) using an
autoanalyzer (Hitachi 7350, Hitachi Ltd, Tokyo, Japan or RX-20,
JEOL Ltd, Tokyo, Japan). The median for serum creatinine was
1.0 mg/dl for male subjects and 0.8 mg/dl for female subjects over
the 10 years of the study.
GFR was estimated from adjusted serum creatinine using the
simplified equation developed from the MDRD Study7 as follows:
GFR (ml/min/1.73 m2)¼ 186.3 (serum creatinine)1.154
age0.203 (0.742 for female subjects).
The serum creatinine value used for the MDRD equation was
measured at the Cleveland Clinic Laboratory as the measurement of
serum creatinine can vary across different laboratories. Serum
creatinine was calibrated as previously described.30 First, the
National Health and Nutrition Examination Survey III creatinine
value was calibrated to the Cleveland Clinic Laboratory, requiring
a correction factor of 0.23 mg/dl. Then, mean creatinine values
from our study, by gender-specific age groups, were aligned with
the corresponding corrected National Health and Nutrition
Examination Survey III age-specific and sex-specific means.
Overall mean differences between National Health and Nutrition
Examination Survey III and our cohort were 0.17 mg/dl. Conse-
quently, we reduced 0.06 from each creatinine value before
calculating GFR.
Measurements of blood glucose, total cholesterol, triglycerides,
and HDL-C were measured using an autoanalyzer (Hitachi 7350,
Hitachi Ltd, Tokyo, Japan or RX-20, JEOL Ltd, Tokyo, Japan).
Hypertension was defined according to World Health Organiza-
tion blood pressure criteria and the use of antihypertensive
medications in 1993 as follows: subjects taking antihypertensive
medication at the baseline were defined as hypertension-treated
(treated hypertension); subjects having systolic blood pressure
X140 mm Hg and diastolic blood pressure X90 mm Hg were
defined as hypertensive. Diabetes was defined as follows: subjects
who were receiving oral hypoglycemic or insulin treatment were
defined as treated diabetes; subjects with fasting blood sugarX
126 mg/dl or random blood sugarX200 mg/dl were defined as
diabetic; subjects with fasting blood sugar levels between 110
and 126 mg/dl or random blood sugar level between 140 and
200 mg/dl were defined as IGT. Hypercholesterolemia was defined
as total cholesterolX220 mg/dl, low HDL-C was defined as HDL-
Cp35 mg/dl, and hypertriglyceridemia was defined as triglycerides
X250 mg/dl.
Alcohol intake was defined as follows: total alcohol consumption
in grams per day was calculated from questions on the number of
glasses of wine, beer, fortified wines, sake, and liqueurs/spirits per
day. One glass of any alcoholic beverage was assumed to contain 10 g
of alcohol. The total alcohol consumption was then classified into
four categories: No alcohol consumption, occasional alcohol
consumption, less than 20 g/day, and more than 20 g/day.
Smoking habits were classified into three categories: non-smoker,
previous smoker, or current smoker. Obesity was defined as a body
mass index X25 kg/m2, calculated as body weight in kilograms
divided by the square of the height in meters.
Table 5 | Classification of CKD among 191 066 adults at initial screening held in 1993
Male Female
Stage n % Mean age (years) Age range (years) n % Mean age (years) Age range (years)
I 365 0.6 58 40–86 338 0.3 52 40–79
II 1340 2.0 65 40–94 1519 1.2 63 40–89
III 3724 5.7 71 40–98 9487 7.5 70 40–96
IV 65 0.1 73 53–91 95 0.1 70 41–91
V 27 0.0 68 45–88 15 0.0 65 42–83
Total 5521 8.4 11 454 9.1
CKD, chronic kidney disease.
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Statistical methods
The primary outcome for the analysis was an estimate of
GFRo60 ml/min/1.73 m2. (CKD stage III or higher) and the
development of proteinuria (CKD stage I or II) during the follow-
up period. Variables were age, proteinuria (categorized as (, þ ,
and þ þ ), or more), hematuria (categorized as (, þ , and þ þ ),
or more), concomitant proteinuria and hematuria (, þ ), IGT
(, þ ), diabetes (, þ , and treated diabetes), hypertension (categor-
ized as systolic blood pressure 140 mm Hg and/or diastolic blood
pressure 90 mm Hg, systolic blood pressure 140–150 mm Hg and/
or diastolic blood pressure 90–95 mm Hg, systolic blood pressure
150–160 mm Hg and/or diastolic blood pressure 95–100 mm Hg,
systolic blood pressure 160 mm Hg and/or diastolic blood pressure
100 mm Hg and treated hypertension), hypercholesterolemia
(, þ ), low HDL-C (, þ ), hypertriglyceridemia (, þ ), obesity
(, þ ), cigarette smoking (never, previous smoker, and current
smoker), alcohol consumption (never, occasional drinker, alcohol
consumptiono20 g/day, and alcohol consumptionX20 g/day). In
the follow-up study of proteinuria, GFR was included as a variable,
but proteinuria, and concomitant proteinuria and hematuria were
excluded from the variables. HRs of renal failure development or
proteinuria development by sex were estimated by using Cox
regression model after confirming the proportionality in each model
(SAS software, version 8.3, SAS Institute Inc., CA, USA). If a variable
was categorical, the first category in the parenthesis in the previous
definition was defined as the baseline in the Cox model. A P-value of
less than 0.05 was considered statistically significant.
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